Ishii H, Mihai R, Watkinson J C, Kim D S
Department of Ear, Nose and Throat, Head and Neck Surgery St George's Hospital London UK.
Department of Endocrine Surgery John Radcliffe Hospital Oxford UK.
BJS Open. 2018 May 28;2(6):364-370. doi: 10.1002/bjs5.77. eCollection 2018 Dec.
The majority of patients with primary hyperparathyroidism (PHPT) have a single overactive adenoma. Advances in preoperative imaging and surgical adjuncts have given rise to minimally invasive parathyroidectomy (MIP), with lower complication rates in comparison with bilateral neck exploration. Misdiagnosis and undertreatment of multiglandular disease, leading to potentially higher recurrence rates, remains a concern. This study evaluated risks of long-term (1 year or more) recurrence following 'targeted' MIP in PHPT.
Multiple databases were searched for studies published between January 2004 and March 2017, looking at long-term outcomes (1 year or more) following targeted MIP for PHPT. English-language studies, with at least 50 patients and a mean follow-up of 1 year, were included.
A total of 5282 patients from 14 studies were included. Overall mean recurrence and cure rates were 1·6 (range 0-3·5) and 96·9 (95·5-100) per cent respectively. Mean follow-up was 33·5 (1-145) months. When intraoperative parathyroid hormone (PTH) measurements were not done, cure rates were higher (99·3 per cent versus 98·1 per cent with use of intraoperative PTH measurement; P < 0·001) and recurrence rates lower (0·2 versus 1·5 per cent respectively; P < 0·001).
Targeted MIP for a presumed single overactive adenoma was associated with very low recurrence rates, without the need for intraoperative PTH measurement when preoperative imaging studies were concordant. Targeted MIP should be encouraged.
大多数原发性甲状旁腺功能亢进症(PHPT)患者有一个功能亢进的腺瘤。术前影像学和手术辅助技术的进步催生了微创甲状旁腺切除术(MIP),与双侧颈部探查相比,其并发症发生率更低。多腺体疾病的误诊和治疗不足导致潜在的更高复发率,这仍然是一个问题。本研究评估了PHPT患者“靶向”MIP术后长期(1年或更长时间)复发的风险。
检索多个数据库,查找2004年1月至2017年3月发表的关于PHPT患者靶向MIP术后长期(1年或更长时间)结局的研究。纳入至少有50例患者且平均随访时间为1年的英文研究。
共纳入14项研究中的5282例患者。总体平均复发率和治愈率分别为1.6%(范围0 - 3.5%)和96.9%(95.5% - 100%)。平均随访时间为33.5个月(1 - 145个月)。未进行术中甲状旁腺激素(PTH)测量时,治愈率更高(99.3%对比使用术中PTH测量时的98.1%;P < 0.001),复发率更低(分别为0.2%对比1.5%;P < 0.001)。
对于假定的单个功能亢进腺瘤进行靶向MIP,复发率非常低,当术前影像学检查结果一致时无需进行术中PTH测量。应鼓励采用靶向MIP。